MBTPS1 and multiple sclerosis: Of late, drugs modulating the SPK1/S1P pathway have been studied as disease modifying treatment in multiple sclerosis, namely the monoclonal antibody (Sphingomab® (20) and an oral S1P receptor modulator, fingolimod (21), and it would be of clinical relevance to assess the impact these drugs may have on LUTD.